Nurix reports Q3 2026 results as bexobrutideg enters Phase 3 and NX-2127 is dropped

Nurix Therapeutics reported financial results on October 12, 2026 for the fiscal quarter ended August 31, 2026, alongside a set of pipeline updates. During the quarter, Nurix and Roche entered into a global collaboration to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology and neurology, cleared the Hart-Scott-Rodino requirement, and began executing with the initiation of the Phase 3 DAYBreak CLL-306 study.¹ Under the deal, development costs are shared 40% by Nurix and 60% by Roche, profits and losses in the United States will be shared equally, and Nurix is eligible for tiered royalties on ex-U.S. sales.¹

The company said it enrolled the first patient in DAYBreak CLL-306 (NCT07516093), the first Phase 3 trial of bexobrutideg.¹ The trial is a randomized study assigning patients 1:1 to bexobrutideg 600 mg orally once daily or pirtobrutinib, with dual primary endpoints of objective response rate and progression-free survival assessed by an independent review committee.¹ Separately, Nurix continued enrollment in DAYBreak CLL-201 (NCT07221500), the pivotal single-arm Phase 2 trial designed to support a potential Accelerated Approval submission.¹ The company also initiated recruiting for the Phase 1b/2 NX-5948-203 study, with its initial cohort evaluating bexobrutideg in combination with venetoclax.¹

In its wholly owned oncology portfolio, Nurix advanced NX-1607, an oral CBL-B inhibitor, into Phase 1b monotherapy expansion cohorts and a Phase 1a combination cohort with pembrolizumab, dosing its first patients in September 2026 across MSS colorectal cancer, NSCLC, CRPC and melanoma.¹ The company also said it made the decision to discontinue further clinical development of its drug candidate known as NX-2127, as part of a broader prioritization effort for its internal oncology programs.¹ Patients currently on NX-2127 may continue treatment as clinically appropriate, with safety monitoring and institutional follow-up continuing.¹

On partnerships, Sanofi's dosing of the first patient in its STAT6 degrader trial triggered a $10 million milestone, and Nurix has now earned approximately $139 million under the Sanofi collaboration, with about $455 million in potential future milestones remaining.¹

Following the Roche collaboration close, the company reported cash, cash equivalents and marketable securities of $1.1 billion as of the end of the quarter, up from $592.9 million roughly nine months earlier,¹ which it said gives it runway into the second half of 2029.